Immunoscintigraphy using 111In-labelled F(ab′)2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma

Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.

“…-46-10 1214-17 Less information is available, however, concerning the staging potential of this technique.8101214-17 Excluding the data shown in the current report, all available information is restricted to about 100 patients and is limited by the inhomogeneity of studies.8 [14][15][16][17] For example, different commercially available immunoreagents (including the F(ab')2 fragments of the F6 antibody,'5 the F(ab')2 fragments of BW431/3 ,14 and the intact BW43 1/268 14 15) have been used and labelled to different radionuclides (indiumll 14 16 technetium-99,81415 and iodine-i 3117). Furthermore, the clinical target has varied in the different studies up to the extreme in the study of MacMillan et al15 who only considered patients with small cell lung cancer, and no separate analysis has been made for lymphatic spread and direct invasion of mediastinum.8 1415 Above all, SPECT images were not always obtained.8 1415 This has caused inconsistent results with sensitivities in the range 40-75% and specificities in the range of 33-81%.8 14-17 Because of these inconsistencies we believe that the results of our study on the value of anti-CEA immunoscintigraphy in the preoperative mediastinal assessment are important.…”

Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer

“…17 46 19 5 87 77% (60% to 95%) 71% (60% to 82%) 72% (63% to 82%) 47% (31% to 64%) 90% (82% to 981yo) immunoscintigraphy Thoracic CT 14 49 16 8 87 64% (44% to 84%) 75% (65% to 86%) 72% (63% to 82%) 47% (29% to 65%) 86% (77% to 95%) scanning Assessable patients with lung cancer Planar 10 51 7 12 80 45% (25% to 66%) 88% (80% to 96%) 76% (67% to 86%) 59% (35% to 82%) 81% (71% to 91%) immunoscintigraphy SPECT 17 42 16 5 80…”

“…In patients with lung cancer several studies have shown that immunoscintigraphy may detect the primary tumour and the possible presence of regional and distant metastases. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] In 13 of 17 clinical investigations so far available for evaluation, tumour targeting was attempted with anti-carcinoembryonic antigen (CEA) antibodies 2-46-101214-17 and anti-CEA immunoscintigraphy can be regarded as the standard for immunoscintigraphic diagnosis. In a recent review of studies of anti-CEA immunoscintigraphy in lung cancer'9 the average detection rates for primary, mediastinal, and distant tumour metastases were 87% (216 of 248 patients), 70% (49 of 70), and 84% (109 of 130), respectively.…”